Isis and Alnylam Announce Issued U.S. Patent Broadly Covering Chemical Modifications of Oligonucleotide Therapeutics
The new '517 patent stems from the Cook patent series that includes three previously issued U.S. patents (U.S. Patent Nos. 5,670,633; 6,005,087; and 6,531,584), and its claims broadly cover oligonucleotide compositions containing more than one 2'-ribose modifications such as 2'-O-methyl and 2'-fluoro groups. According to Alnylam, these chemical modifications can be used to improve potency and stability of siRNAs and can also be used to optimize their selectivity.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.